Deramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal ...
Deramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, ...
CESTAT Allahabad held that demand invoking extended period of limitation cannot be sustained since there was bona fide that services fall under negative list. Accordingly, appeal is allowed and order ...
Artificial intelligence is no longer a fringe topic in newsrooms; it’s reshaping how journalism is produced, distributed, moderated, and monetized.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results